CGEM vs FDMT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CGEM Captures Institutional Edge (3โ1 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cullinan Therapeutics, Inc. Common Stock (CGEM) driven by superior Valuation, Growth & Margin, Options & Structure while FDMT counters with relative strength in Momentum & Technical. Fundamentally, CGEM trades at 6.7x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus FDMT at N/M Forward P/E and -222.7% operating margin (+4505.6% YoY). In options structure, CGEM sits in UNCLASSIFIED (9th %ile IV; Dealer Gamma Walls on Pro) against FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CGEM | FDMT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $653.8M | $669.3M | Larger Scale | FDMT |
| Trailing P/E Ratio Valuation | 6.7x | N/M | Lower Multiple | CGEM |
| Forward P/E Ratio Valuation | 6.7x | N/M | Lower Multiple | CGEM |
| Revenue Growth (YoY) Growth | +0.0% | +4505.6% | Higher Growth | FDMT |
| Operating Margin (TTM) Profitability | 0.0% | -222.7% | Higher Margin | CGEM |
| Net Profit Margin Profitability | 0.0% | -208.6% | Higher Margin | CGEM |
| Return on Equity (ROE) Capital Efficiency | -50.3% | -56.7% | Higher ROE | CGEM |
| 52-Week Range Position Momentum | 12% ($8โ$23) | 47% ($7โ$17) | Stronger Trend | FDMT |
| Beta / 30D Volatility Risk Regime | 1.56ฮฒ ยท 104% Vol | 1.89ฮฒ ยท 90% Vol | Lower Realized Risk | FDMT |
| Unified Institutional Score Composite Signal | 41.0 / 100 (SELL) | 51.3 / 100 (HOLD) | Higher Composite | FDMT |